NCT01288027View on ClinicalTrials.gov

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Pompe Disease (Late-Onset)Glycogen Storage Disease Type II (GSD II)Glycogenesis 2 Acid Maltase Deficiency

Interventions

BIOLOGICAL

Alglucosidase Alfa

Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.

Trial Locations (15)

Unknown

Orange

Gainesville

Kansas City

St Louis

New York

Durham

Colombus

Heshey

Fairfax

Mainz

München

Münster

Rotterdam

Newcastle upon Tyne

Salford

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01288027 - Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa | Biotech Hunter | Biotech Hunter